1. Home
  2. IGR vs LBRX Comparison

IGR vs LBRX Comparison

Compare IGR & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CBRE Global Real Estate Income Fund of Beneficial Interest

IGR

CBRE Global Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$4.40

Market Cap

645.2M

Sector

Finance

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

N/A

Current Price

$25.61

Market Cap

602.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IGR
LBRX
Founded
2004
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
645.2M
602.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IGR
LBRX
Price
$4.40
$25.61
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$50.67
AVG Volume (30 Days)
702.6K
209.4K
Earning Date
01-01-0001
05-09-2026
Dividend Yield
13.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.15
$13.40
52 Week High
$5.37
$27.55

Technical Indicators

Market Signals
Indicator
IGR
LBRX
Relative Strength Index (RSI) 44.46 59.48
Support Level $4.20 $22.39
Resistance Level $5.04 $27.55
Average True Range (ATR) 0.10 1.49
MACD 0.00 0.06
Stochastic Oscillator 50.91 63.31

Price Performance

Historical Comparison
IGR
LBRX

About IGR CBRE Global Real Estate Income Fund of Beneficial Interest

CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Share on Social Networks: